" We did studies with MRI looking at the brains of aging populations and wondered if we can correlate the cognitive abilities with the status of the blood brain barrier in the hippocampus, which we can. Then, we stained postmortem brains of different ages that were neurologically intact, and we noticed an increase of age in this blood protein in those astrocytes with the activity of the receptor. Then, we went to brains donated by Alzheimer’s patients, and you definitely see a very big increase in those three markers that are colocalized in the brains of Alzheimer’s patients. So there are a lot of reasons that the clinical trials in mice work are applicable to humans. We’re at the point where we’re trying to fundraise for the company that develops the drug. "